Immune Therapy Holdings

Immune Therapy Holdings is a private Swedish biotechnology and medical device-oriented R&D company focused on immunotherapy and diagnostics for immune-related diseases. Its core technology is Tailored Leukapheresis (TLA), an extracorporeal cell-selective leukapheresis approach designed to remove disease-driving inflammatory cells from circulation. The company has positioned TLA for immune-mediated inflammatory diseases, particularly inflammatory bowel disease, and has also referenced broader IMID applications such as rheumatologic and autoimmune disorders. Immune Therapy Holdings appears to operate as a holding and development company around the TLA platform and related ventures, including TLA Targeted Immunotherapies. Publicly available information suggests the company remains active as a Swedish legal entity, although its operating subsidiary TLA Targeted Immunotherapies entered bankruptcy in 2025.